Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorThe First Affiliated Hospital of Soochow University
About this trial
This study aims to evaluate the efficacy of combining pirtobrutinib, lisaftoclax, and rituximab (PVR) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have received at least one prior line of systemic therapy and to explore a more effective treatment strategy for this patient population.
Eligibility criteria
Qualifiers
≥18 years old.
Capable of understanding and voluntarily signing written informed consent.
ECOG performance 0 ~ 3.
Anticipated survival ≥3 months
Disqualifiers
Prior treatment failure or resistance to pirtobrutinib or BCL2 inhibitors.
Prior Anticancer Therapy:Chemotherapy, radiotherapy, immunotherapy, or antibody-based anticancer therapy within the specified washout period.Traditional Chinese herbal medicine with antitumor indications.Small-molecule targeted therapy within 2 weeks before study treatment initiation. ADCs or cytotoxic therapy within 10 weeks before study treatment initiation.
Participation in another investigational drug study within 4 weeks prior to the first dose of study treatment.
Systemic corticosteroid therapy (>5 days within 14 days prior to treatment) at doses exceeding >10 mg/day dexamethasone (or equivalent) for CNS disease control.
Trial design
Treatments tested in this trial
- Pirtobrutinib
- Lisaftoclax
- Rituximab
Treatment groups
29 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov